UBS Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

UBS Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,000	Closed	-$659K	–	10859
2025 Q3	$659K	Buy	+5,000	New	+$600K	﹤0.01%	5892
2018 Q3	–	Sell	-141,400	Closed	-$24.4M	–	8111
2018 Q2	$24.4M	Buy	+141,400	New	+$23.1M	0.01%	1047
2017 Q1	–	Sell	-52,500	Closed	-$5.72M	–	7786
2016 Q4	$5.72M	Buy	52,500 +20,000	+62%	+$2.23M	﹤0.01%	1974
2016 Q3	$3.95M	Buy	+32,500	New	+$4.38M	﹤0.01%	2243
2016 Q1	–	Sell	-700	Closed	-$98K	–	7891
2015 Q4	$98K	Hold	700	–	–	﹤0.01%	5229
2015 Q3	$93K	Hold	700	–	–	﹤0.01%	5289
2015 Q2	$123K	Sell	700 -2,400	-77%	-$431K	﹤0.01%	5241
2015 Q1	$536K	Sell	3,100 -4,600	-60%	-$789K	﹤0.01%	4085
2014 Q4	$1.26M	Buy	+7,700	New	+$1.28M	﹤0.01%	3384

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

UBS Group's JAZZ Position: Q1 2026 in Review

UBS Group reduced its Jazz Pharmaceuticals (JAZZ) stake by 24% in Q1 2026, selling an estimated $20.2M and leaving 357,203 shares worth $67.5M. The position accounts for 0.01% of the portfolio, ranked #1350.

UBS Group first reported a position in JAZZ in Q4 2014 and has held it in 46 quarters since. The position peaked at $80.4M in Q4 2025. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

UBS Group held 357,203 shares of Jazz Pharmaceuticals worth $67.5M as of Q1 2026.
UBS Group sold 115,749 Jazz Pharmaceuticals shares in Q1 2026, an estimated $20.2M.
Jazz Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q1 2026, its #1350 holding.
UBS Group first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
UBS Group's Jazz Pharmaceuticals position peaked at $80.4M in Q4 2025.
571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.